(Reuters) -Health and Human Services Secretary Robert F. Kennedy Jr. said on Thursday that the U.S. drugs regulator would ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced ...

Consequently, RNAi therapeutics as a drug class have the potential to exert a transformational effect on modern medicine. In RNAi, the target mRNA is enzymatically cleaved, leading to decreased ...

Projection is an analytical tool that visualizes the expected change in an asset's price in the next 90 days based on activity in the options market.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S ...

Crispr Therapeutics said it is partnering with Sirius Therapeutics to develop and commercialize SRSD107, a small interfering RNA therapy to treat thromboembolic disorders. Under the agreement ...

NEW ORLEANS – Certain markers of gene-splicing correction may predict functional improvements among myotonic dystrophy type 1 (DM1) patients treated with Dyne Therapeutics' investigational antisense ...